Year:  2017 2018 2019 2020 2021 2022 2023 2024 2025 

QPP Measure #452

Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies

Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer and RAS (KRAS or NRAS) gene mutation spared treatment with anti-EGFR monoclonal antibodies.

Submission Methods: Registry
Measure Sets: Oncology

The following codes apply for this QPP measure:

HCPCS Codes

CodeDescription
M0001Advancing cancer care mips value pathways
demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.